N-803 and BCG + N-803
Phase 2/3Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Jun 2, 2017 → Mar 1, 2029
NCT ID
NCT03022825About N-803 and BCG + N-803
N-803 and BCG + N-803 is a phase 2/3 stage product being developed by ImmunityBio for Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03022825. Target conditions include Bladder Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Bladder Cancer were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
15
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03022825 | Phase 2/3 | Active |
Competing Products
20 competing products in Bladder Cancer